» Articles » PMID: 8125142

Two Tyrosinase Nonapeptides Recognized on HLA-A2 Melanomas by Autologous Cytolytic T Lymphocytes

Overview
Journal Eur J Immunol
Date 1994 Mar 1
PMID 8125142
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

A number of cytolytic T lymphocyte (CTL) clones derived from several melanoma patients have been found to recognize a majority of melanomas from HLA-A2 patients. We have reported previously that two such CTL clones recognize a product of the tyrosinase gene that is presented by HLA-A2. Here we show that one of these CTL clones recognizes a peptide encoded by the first nine amino acids of the putative signal sequence of tyrosinase. The other CTL clone recognizes a different tyrosinase peptide corresponding to amino acids 368-376. Both peptides contain consensus motifs of HLA-A2 binding peptides.

Citing Articles

Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Alarcon N, Jaramillo M, Mansour H, Sun B Pharmaceutics. 2022; 14(7).

PMID: 35890342 PMC: 9325128. DOI: 10.3390/pharmaceutics14071448.


Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy.

Davis L, Tarduno A, Lu Y Cancers (Basel). 2021; 13(23).

PMID: 34885172 PMC: 8657037. DOI: 10.3390/cancers13236061.


HLA-DRB116:01 and HLA-DQB105:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.

Wang X, Almazan F, Montoyo-Pujol Y, Martin-Casares A, Martin A, Cabrera T J Oncol. 2021; 2021:3801143.

PMID: 34630564 PMC: 8497119. DOI: 10.1155/2021/3801143.


Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Balhorn R, Balhorn M Oncotarget. 2020; 11(35):3315-3349.

PMID: 32934776 PMC: 7476732. DOI: 10.18632/oncotarget.27709.


Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.

Mac Keon S, Bentivegna S, Levy E, Marks M, Mantegazza A, Wainstok R Vaccine. 2019; 37(35):4947-4955.

PMID: 31307876 PMC: 7713901. DOI: 10.1016/j.vaccine.2019.07.018.